CLYM vs ZBIO

Head-to-Head Stock Analysis & Investment Rating

Last Updated: Aug 24, 2026

CLYM

33.3
AI Score
VS
ZBIO Wins

ZBIO

62.0
AI Score

Investment Advisor Scores

CLYM

33score
Recommendation
SELL

ZBIO

62score
Recommendation
BUY

AI Analyst Insights

AI insights temporarily unavailable

Detailed Metrics Comparison

Metric CLYM ZBIO Winner
Net Income -27.22M -377.74M CLYM
Operating Income -30.57M -383.06M CLYM
ROE -11.4% -156.0% CLYM
ROA -11.1% -98.5% CLYM
Total Assets 246.29M 383.64M ZBIO
Cash 44.11M 110.64M ZBIO
Current Ratio 31.45 5.61 CLYM
Free Cash Flow -25.18M -172.35M CLYM

Relative Price Performance (Last 90 Days)

CLYM 1M: +27.7% · 3M: +49.1% ZBIO 1M: +4.1% · 3M: +66.8%

Current Technical Phase

CLYM

Markup
Hold / add on dips

Price above SMA50, rising 50-day trend (11.8% over 20 days), RSI 64

RSI (14): 64.4 · Price: $16.40

ZBIO

Markup
Hold / add on dips

Price above SMA50, rising 50-day trend (23.0% over 20 days), RSI 55

RSI (14): 55.4 · Price: $31.65

Fundamentals Snapshot

Metric CLYM ZBIO
Market Cap
Forward P/E -15.5 -6.8
Trailing P/E
Revenue (TTM)
Revenue Growth 0.0% -1.0%
Gross Margin -212.5%
Operating Margin 0.0% -77.7%
EPS -0.82 -9.63
Dividend Yield

Frequently Asked Questions

Based on our detailed analysis, ZBIO is currently the stronger investment candidate, winning 2 of the key financial metrics based on our comprehensive scoring model.

We analyze revenue and earnings growth rates in the "Growth" section above. Generally, the company with higher year-over-year revenue and EPS growth is fostering better expansion. Check the table above for the specific growth percentages.

Valuation is determined by metrics like the P/E Ratio and PEG Ratio. A lower P/E typically suggests a stock is cheaper relative to its earnings. Refer to the "Valuation" section in our comparison table to see which stock currently trades at a more attractive multiple.